Atypical Parkinsonism

Neurological Disorders: Course and Treatment: Second Edition

Volumn , Issue , 2003, Pages 1081-1098

  Poewe, Werner ^a   Wenning, Gregor K ^a  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 26444552224     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012125831-3/50270-7     Document Type: Chapter

References (116)

1. Alam M., Smith G., Bleasdale-Barr K., Pavitt D.V., Mathias C.J. Effects of the peptide release inhibitor, octreotide, on daytime hypotension and on nocturnal hypertension in primary autonomic failure. J. Hypertens. 1995, 13:1664-1669.
2. Barclay C.L., Duff J., Sandor P., Lang A.E. Limited usefulness of electroconvulsive therapy in progressive supranuclear palsy. Neurology 1996, 46:1284-1286.
3. Barclay C.L., Lang A.E. Dystonia in progressive supranuclear palsy. J. Neurol. Neurosurg. Psychiat. 1997, 62:352-356.
4. Beck R.O., Betts C.D., Fowler C.J. Genitourinary dysfunction in multiple system atrophy: clinical features and treatment in 62 cases. J. Urol. 1994, 151:1336-1341.
5. Ben-Shlomo Y., Wenning G.K., Tison F., Quinn N.P. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology 1997, 48:384-393.
6. Boesch S.M., Wenning G.K., Ransmayr G., Poewe W. Dystonia in multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 2002, 72(3):300-303.
7. Bower J.H., Maraganore D.M., McDonnell S.K., Rocca W.A. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997, 49:1284-1288.
8. Colosimo C., Merello M., Pontieri F.E. Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study. J. Neurol. 1996, 243:422-425.
9. Daniele A., Moro E., Bentivoglio A.R. Zolpidem in progressive supranuclear palsy. N. Engl. J. Med. 1999, 341(7):543-544.
10. Di Maria E., Tabaton M., Vigo T., Abbruzzese G., Bellone E., Donati C., Frasson E., Marchese R., Montagna P., Munoz D.G., Pramstaller P.P., Zanusso G., Ajmar F., Mandich P. Coritcobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann. Neurol. 2000, 47:374-377.
11. Duncombe A.S., Lees A.J. Methysergide in progressive supranuclear palsy. Neurology 1985, 35:936-937.
12. Engel P.A. Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects. J. Am. Geriatr. Soc. 1996, 44:1072-1074.
13. Fabbrini G., Barbanti P., Bonifati V., Colosimo C., Gasparini M., Vanacore N., Meco G. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol. Scand. 2001, 103:123-125.
14. Foster N.L., Aldrich M.S., Bluemlein L., White R.F., Berent S. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 1989, 39:257-261.
15. Ghika J., Tennis M., Hoffman E., Schoenfeld D., Growdon J. Idazoxan treatment in progressive supranuclear palsy. Neurology 1991, 41:986-991.
16. Gilman S., Low P.A., Quinn N., Albanese A., Ben-Shlomo Y., Fowler C.J., Kaufmann H., Klockgether T., Lang A.E., Lantos P.L., Litvan I., Mathias C.J., Oliver E., Robertson D., Schatz I., Wenning G.K. Consensus statement on the diagnosis of multiple system atrophy. J. Neurol. Sci. 1999, 163(1):94-98.
17. Golbe L.I., Langston J.W., Shoulson I. Selegiline and Parkinson's disease. Protective and symptomatic considerations. Drugs 1990, 39:646-651.
18. Graham J.G., Oppenheimer D.R. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J. Neurol. Neurosurg. Psychiat. 1969, 32:28-34.
19. Hauser R.A., Trehan R. Initial experience with electroconvulsive therapy for progressive supranuclear palsy. Mov. Disord. 1994, 9:467-469.
20. Hughes A.J., Colosimo C., Kleedorfer B., Daniel S.E., Lees A.J. The dopaminergic response in multiple system atrophy. J. Neurol. Neurosurg. Psychiat. 1992, 55:1009-1013.
21. Iranzo A., Santamaria J., Tolosa E. Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Barcelona Multiple System Atrophy Study Group. Lancet 2000, 356:1329-1330.
22. Jackson J.A., Jankovic J., Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann. Neurol. 1983, 13:273-278.
23. Jankovic J. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy. Neurology 1983, 33:505-507.
24. Jankovic J., Gilden J.L., Hiner B.C., Kaufmann H., Brown D.C., Coghlan C.H., Rubin M., Fouad-Tarazi F.M. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am. J. Med. 1993, 95:38-48.
25. Johnsen J.A., Miller V.T. Tobacco intolerance in multiple system atrophy. Neurology 1986, 36:986-988.
26. Koller W.C., Morantz R., Vetere-Overfield B., Waxman M. Autologous adrenal medullary transplant in progressive supranuclear palsy. Neurology 1989, 39:1066-1068.
27. Kompoliti K., Goetz C.G., Litvan I., Jellinger K., Verny M. Pharmacological therapy in progressive supranuclear palsy. Arch. Neurol. 1998, 55:1099-1102.
28. Lees A.J. The treatment of the motor disorders of multiple system atrophy. Autonomic Failure 1999, 357-363. Oxford University Press. C.J. Mathias, R. Bannister (Eds.).
29. Lees A.J., Bannister R. The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager syndrome). J. Neurol. Neurosurg. Psychiat. 1981, 44:347-351.
30. Litvan I., Blesa R., Clark K., Nichelli P., Atack J.R., Mouradian M.M., Grafman J., Chase T.N. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy. Ann. Neurol. 1994, 36:55-61.
31. Litvan I., Chase T.N. Traditional and experimental therapeutic approaches. Progressive Supranuclear Palsy 1992, 254-269. Oxford University Press. I. Litvan, Y. Agid (Eds.).
32. Litvan I., Agid Y., Calne D., Campbell G., Dubois B., Duvoisin R.C., Goetz C.G., Golbe L.I., Grafman J., Growdon J.H., Hallett M., Jankovic J., Quinn N.P., Tolosa E., Zee D.S. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996, 47:1-9.
33. Litvan I., Mangone C.A., McKee A., Verny M., Parsa A., Jellinger K., D'Olhaberriague L., Chaudhuri K.R., Pearce R.K. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J. Neurol. Neurosurg. Psychiat. 1996, 60:615-620.
34. Low P.A., Gilden J.L., Freeman R., Sheng K.N., McElligott M.A. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997, 277:1046-1051.
35. Mathias C.J., Fosbraey P., da Costa D.F., Thornley A., Bannister R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br. Med. J. (Clin Res Ed) 1986, 293:353-354.
36. Mathias C.J., Kimber J.R. Postural hypotension: Causes, clinical features, investigation, and management. Annu. Rev. Med. 1999, 50:317-336.
37. Mathias C.J., Senard J.M., Braune S., Watson L., Aragishi A., Keeling J.E., Taylor M.D. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: A multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin. Auton. Res. 2001, 11(4):235-242.
38. Mueller J., Wenning G.K., Wissel J., Seppi K., Poewe W. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J. Neurol. 2002, 249(3):300-304.
39. Nagasaka T., Togashi S., Amino A., Nitta K., Shindo K., Shiozawa Z. Aniracetam for treatment of patients with progressive supranuclear palsy. Eur. Neurol. 1997, 37:195-198.
40. Neophytides A., Lieberman A.N., Goldstein M., Gopinathan G., Leibowitz M., Bock J., Walker R. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. J. Neurol. Neurosurg. Psychiat. 1982, 45:261-263.
41. Newman G.C. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 1985, 35:1189-1193.
42. Nieforth K.A., Golbe L.I. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin. Neuropharmacol. 1993, 16:338-346.
43. Parati E.A., Fetoni V., Geminiani G.C., Soliveri P., Giovannini P., Testa D., Genitrini S., Caraceni T., Girotti F. Response to L-DOPA in multiple system atrophy. Clin. Neuropharmacol. 1993, 16:139-144.
44. Paulson G.W., Lowery H.W., Taylor G.C. Progressive supranuclear palsy: pneumoencephalography, electronystagmography and treatment with methysergide. Eur. Neurol. 1981, 20:13-16.
45. Perera R., Isola L., Kaufmann H. Effect of recombinant erythropoietin on anemia and orthostatic hypotension in primary autonomic failure. Clin. Auton. Res. 1995, 5:211-213.
46. Piccione F., Mancini E., Tonin P., Bizzarini M. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch. Phys. Med. Rehabil. 1997, 78:525-529.
47. Polo K.B., Jabbari B. Botulinum toxin-A improves the rigidity of progressive supranuclear palsy. Ann. Neurol. 1994, 35:237-239.
48. Rafal R.D., Grimm R.J. Progressive supranuclear palsy: functional analysis of the response to methysergide and antiparkinsonian agents. Neurology 1981, 31:1507-1518.
49. Raimbach S.J., Cortelli P., Kooner J.S., Bannister R., Bloom S.R., Mathias C.J. Prevention of glucose-induced hypotension by the somatostatin analogue octreotide (SMS 201-995) in chronic autonomic failure: haemodynamic and hormonal changes. Clin. Sci. (Lond.) 1989, 77:623-628.
50. Rascol O., Sieradzan K., Peyro-Saint-Paul H., Thalamas C., Brefel-Courbon C., Senard J.M., Ladure P., Montastruc J.L., Lees A. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear plasy. Mov. Disord. 1998, 13:673-676.
51. Sakakibara R., Hattori T., Uchiyama T., Suenaga T., Takahashi H., Yamanishi T., Egoshi K., Sekita N. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J. Auton. Nerv. Syst. 2000, 79:191-195.
52. Schrag A., Ben-Shlomo Y., Quinn N.P. Prevalence of progressive supranuclear palsy and multiple system atrophy: A cross-sectional study. Lancet 1999, 354:1771-1775.
53. Tamai S., Almeida O.P. Nortriptyline for the treatment of depression in progressive supranuclear palsy. J. Am. Geriatr. Soc. 1997, 45:1033-1034.
54. Tison F., Wenning G.K., Daniel S.E., Quinn N.P. The pathophysiology of parkinsonism in multiple system atrophy. Eur. J. Neurol. 1995, 2:435-444.
55. Watanabe H., Saito Y., Terao S., Ando T., Kachi T., Mukai E., et al. Progression and prognosis in multiple system atrophy: An analysis of 230 Japanese patients. Brain 2002, 125(Pt 5):1070-1083.
56. Waxman M.J., Morantz R.A., Koller W.C., Paone D.B., Nelson P.W. High incidence of cardiopulmonary complications associated with implantation of adrenal medullary tissue into the caudate nucleus in patients with advanced neurologic disease. Crit. Care Med. 1991, 19:181-186.
57. Weiner W.J., Minagar A., Shulman L.M. Pramipexole in progressive supranuclear palsy. Neurology 1999, 52:873-874.
58. Wenning G.K., Ben-Shlomo Y., Hughes A., Daniel S.E., Lees A., Quinn N.P. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?. J. Neurol. Neurosurg. Psychiat. 2000, 68:434-440.
59. Wenning G.K., Ben-Shlomo Y., Magalhaes M., Daniel S.E., Quinn N.P. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 1994, 117:835-845.
60. Williams A.C., Nutt J., Lakes C.R., et al. Actions of bromocriptine in the Shy-Drager and Steele-Richardson-Olszewski syndrome. Dopaminergic Ergots and Motor Control 1979, 271-283. Pergamon Press, Oxford. K. Fixe, D.B. Calne (Eds.).
61. Winkler A.S., Marsden J., Parton M., Watkins P.J., Chaudhuri K.R. Erythropoietin deficiency and anaemia in multiple system atrophy. Mov. Disord. 2001, 16:233-239.
62. Zesiewicz T.A., Helal M., Hauser R.A. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parinson's disease. Mov. Disord. 2000, 15:305-308.
63. Aarsland D., Larsen J.P., Lim N.G., Tandberg E. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J. Neuropsychiatry Clin. Neurosci. 1999, 11:392-394.
64. Baldessarini R.J., Frankenburg F.R. Clozapine. A novel antipsychotic agent. N. Engl. J. Med. 1991, 324:746-754.
65. Ballard C., Grace J., McKeith I.G., et al. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease. Lancet 1998, 351:1032-1033.
66. Burke W.J., Pfeiffer R.F., McComb R.D. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J. Neuropsychiatry Clin. Neurosci. 1998, 10(2):227-229.
67. Crystal H.A., Dickson D.W., Lizardi J.E., Davies P., et al. Antemortem diagnosis of diffuse Lewy body disease. Neurology 1990, 40:1523-1528.
68. Cummings J.L. Lewy body diseases with dementia: pathophysiology and treatment. Brain Cognition 1995, 28:266-280.
69. Eichhorn T.E., Brunt E., Oertel W.H. Ondansetron treatment of l-dopa induced psychosis. Neurology 1996, 47:1608-1609.
70. Fergusson E., Howard R. Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int. J. Geriatr. Psychiat. 2000, 15:280-281.
71. Fernandez H.H., Friedman J.H., Jacques C., Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord. 1999, 14:484-487.
72. Ford B., Lynch T., Greene P. Risperidone in Parkinson's disease. Lancet 1994, 434:1370-1371.
73. Friedberg G., Zoldan J., Weizman A., Melamed E. Parkinson Psychosis Rating Scale: a practical instrument of grading psychosis in Parkinson's disease. Clin Neuropharmacol. 1998, 21:280-294.
74. Goetz C.G., Blasucci L.M., Leurgans S., Pappert E.J. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000, 55:748-749.
75. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
76. Lanctot K.L., Herrmann N. Donepezil for behavioral disorders associated with Lewy bodies: a case series. Int. J. Geriatr. Psychiatry 2000, 15:338-345.
77. Lebert F., Pasquier F., Souliez L., Petit H. Tacrine efficacy in Lewy body dementia. Int. J. Geriatr. Psychiatry 1998, 13:516-519.
78. Levy R., Eagger S., Griffiths M., Perry E., et al. Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 1994, 343:176.
79. Mayeux R., Denaro J., Hemenegildo N., Marder K., et al. A population-based invstigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch. Neurol. 1992, 49:492-497.
80. Matheson A.J., Lamb H.M. Quetiapine. A review of its clinical potential in the management of psychotic symptoms in Parkinson's disease. CNS Drugs 2000, 14:157-172.
81. McKeith I.G., Ballard C.G., Perry R.H., Ince P.G., O'Brien J.T., Neill D., et al. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2002, 54(5):1050-1058.
82. McKeith I., Del Ser T., Spano P., Emre M., et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000, 356:2031-2036.
83. McKeith I.G., Fairbairn A., Perry R., et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992, 305:673-678.
84. McKeith I.G., Fairbairn A., Perry E.K., et al. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol. Med. 1992, 22:911-922.
85. McKeith I.G., Galasko D., Kosaka K., Perry E.K., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology 1996, 47:1113-1124.
86. McKeith I.G., Galasko D., Wilcock G.K., Byrne E. Lewy body dementia-diagnosis and treatment. Br. J. Psychia. 1995, 167:709-717.
87. McKeith I.G., Grace J.B., Walker Z., Byrne E.J., et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int. J. Geriatr. Psychiatry 2000, 15:387-392.
88. McKeith I.G., Perry E.K., Perry R.H. Report of the second dementia with Lewy body international workshop: diagnosis and treatment consortium on dementia with Lewy bodies. Neurology 1999, 53:902-905.
89. Morris S.K., Olichney J.M., Corey-Bloom J. Psychosis in dementia with lewy bodies. Semin. Clin. Neuropsychiatry 1998, 3(1):51-60.
90. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med. 1999, 340:757-763. Parkinson Study Group.
91. Parsa, M., Greenway, H., and Bastani, B. (2000). Quetiapine in the treatment of psychosis in patients with Parkinson's disease and dementia (Lewy body disease variant). Annual Meeting of the American Association for Geriatric Psychiatry, Mar 12-15, Miami, Florida.
92. Perry E., Walker M., Grace J., Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci. 1999, 22:273-280.
93. Querfurth H.W., Allam G.J., Geffroy M.A., Schiff H.B., Kaplan R.F. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial. Dement. Geriatr. Cogn. Disord. 2000, 11:314-321.
94. Rich S.S., Friedman J.H., Ott B.R. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J. Clin. Psychiatry 1995, 56:556-559.
95. Rojas-Fernandez C.H. Successful use of donazepil for the treatment of dementia with Lewy bodies. Ann. Pharmacother. 2001, 35:202-205.
96. Samuel W., Caligiuri M., Galasko D., et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with lewy bodies: a preliminary study. Int. J. Geriatr. Psychiatry 2000, 15:794-802.
97. Shea C., MacKnight C., Rockwood K. Aspects of dementia. Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int. Psychogeriatr. 1998, 10:229-238.
98. Skjerve A., Nygaard H.A. Improvement in sundowning in dementia with Lewy bodies after treatment with donepezil. Int. J. Geriatr. Psychiatry 2000, 15:1147-1151.
99. Scholz E., Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperrlapine. Eur. Arch. Psychiatry Neurol. Sci. 1985, 235:60-64.
100. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 1999, 353:2041. The French Clozapine Parkinson Study Group.
101. Walker Z., Grace J., Overshot R., Satarsinghe S., et al. Olanzapine in dementia with Lewy bodies: a clinical study. Int. J. Geriatr. Psychiatry 1999, 14:459-466.
102. Zoldan J., Friedberg G., Livneh M., Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995, 45:1305-1308.
103. Cummings J.L., Litvan I. Neuropsychiatric aspects of corticobasal degeneration. Advances in Neurology 2000, Vol. 82:147-152. Lippincott Williams & Wilkins, Philadelphia. I. Litvan, C.G. Goetz, A.E. Lang (Eds.).
104. Gibb W.R.G., Luthert P.J., Marsden C.D. Corticobasal degeneration. Brain 1989, 112:1171-1192.
105. Kertesz A., Martinez-Lage P., Davidson W., Munoz D.G. The corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia. Neurology 2000, 55:1368-1375.
106. Kompoliti K., Goetz C.G. Therapeutic approaches. Advances in Neurology 2000, Vol. 82:217-221. Lippincott Williams & Wilkins, Philadelphia. I. Litvan, C.G. Goetz, A.E. Lang (Eds.).
107. Kompoliti K., Goetz C.G., Boeve B.F., Maraganore D.M., et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch. Neurol. 1998, 55:957-961.
108. Litvan I. Progressive supranuclear palsy and corticobasal degeneration. Bailliere's Clin. Neurol. 1997, 6:167-185.
109. Litvan I., Agid Y., Goetz C., et al. Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathological study. Neurology 1997, 57:1184-1189.
110. Mueller J., Wenning G.K., Wissel J., Seppi K., Poewe W. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J. Neurol. 2002, 249(3):300-304.
111. Rebeiz J.J., Kolodny E.H., Richardson E.P. Corticodentationigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans. Am. Neurol. Assoc. 1967, 92:23-26.
112. Riley D.E., Lang A.E., Lewis A., Resch L., Ashby P., Hornykiewicz O., et al. Cortical-basal ganglionic degeneration. Neurology 1990, 40:1203-1212.
113. Rinne J.O., Lee M.S., Thompson P.D., Marsden C.D. Corticobasal degeneration: a clinical study of 36 cases. Brain 1994, 117:1183-1196.
114. Vanek Z.F., Jankovic J. Dystonia in corticobasal degeneration. Advances in Neurology 2000, Vol. 82:61-67. Lippincott Williams & Wilkins, Philadelphia. I. Litvan, C.G. Goetz, A.E. Lang (Eds.).
115. Watts R.L., Mirra S.S., Young R.R. Corticobasal ganglionic degeneration. (CBDG) with neuronal achromasia: clinical-pathological study of two cases. Neurology 1989, 39:140.
116. Wenning G.K., Litvan I., Jankovic J., Granata R., et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at post-mortem examination. J. Neurol. Neurosurg. Psychiatry 1998, 64:184-189.